About BioVie Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.bioviepharma.com/
Frequently Asked Questions
What is the 52-week range for BIVI?
The 52-week high is $3.79 and the 52-week low is $0.82.
What is the P/E ratio for BIVI?
The P/E ratio data is currently unavailable.
What is the dividend yield for BIVI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -126.02%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.42.
Analyst Recommendation Trends
Wall Street analyst consensus for BIVI over the last few months:
Latest BIVI News
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p. ET broadcast reaching audiences across the United States, Latin America and MENANEW YORK CITY, NY / ACCESS Newswire / September 26, 2026 / , the financial-media platform for public companies, pre-IPO companies and entrepreneurs, today announced that Show 773 will air tonight at 6:30 p.
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets September 23, 2026 11:00 AM...
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.
Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / September 18, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 19, at 7:00 p.
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - Slideshow
2026-09-17. The following slide deck was published by BioVie Inc.
Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results
BioVie CEO Cuong Do to discuss newly reported Phase 2 data showing bezisterim's potential across key Long COVID symptomsLearn why the ADDRESS-LC findings, together with recent Parkinson's data, could strengthen the case for targeting inflammation and insulin resistance across neurological disordersORLANDO, FL / ACCESS Newswire / September 16, 2026 / RedChip Companies will host an investor webinar on September 23, 2026, at 11:00 a.The exclusive event will feature BioVie President and CEO Cuong Do
BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population
BioVie (NASDAQ:BIVI) shares fell nearly 9. 7% in premarket trading after the company reported results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for neurological symptoms associated with Long COVID.
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid September 15, 2026 8:30 AM EDTCompany...
What's Going On With BioVie Stock on Tuesday?
BioVie reported Phase 2 ADDRESS-LC trial results evaluating bezisterim for Long COVID, showing significant subgroup improvements.
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options Conference call scheduled for 8:30 a.m. today, September 15, 2026, to
BioVie Announces Phase 2 ADDRESS-LC Trial Results Of Bezisterim In Long COVID
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaiseBezisterim showed a
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the Company will host a conference call and webcast on Tuesday, September 15, 2026 at 8:30am ET to discuss topline results from its Phase 2 ADDRESS-LC trial (NCT06847191
BioVie Enters Sales Agreement With Alliance Global Partners For Up To $6,464,341 Of Stock
On September 11, 2026, BioVie Inc., a Nevada corporation (the "Company"), entered into a sales agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Agent"), pursuant to
BioVie’s lead therapy candidate shows improvement in key long COVID symptoms
BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss what the company believes is a significant breakthrough in the treatment of long COVID, reporting that its lead drug candidate, Bezisterim, became the first therapy to demonstrate improvements across the three hallmark symptoms of the condition—fatigue, malaise and brain fog—in a well-controlled clinical trial. Do noted that the National Institutes of Health (NIH) RECOVER Initiative has supported eight clinical studies evaluating 13 different interventions for long COVID, yet none have demonstrated meaningful effectiveness to date. Against that backdrop, he said BioVie’s results stand out as an important milestone in the search for therapies targeting the complex and often debilitating condition. According to Do, the trial delivered three major insights into long COVID and how it may be treated. First, the study confirmed that long COVID is highly heterogeneous, meaning patients experience symptoms very differently. Only about 15% of participants entered the study with severe levels of all three major symptoms, while roughly 20% were not significantly affected by any of them. Second, the data showed that patients must have a meaningful level of symptom severity at baseline in order to demonstrate measurable improvement. This finding may help guide future trial designs and patient selection strategies. Third, and most importantly, patients with a high symptom burden experienced clinically meaningful and statistically significant improvements. Participants suffering from severe fatigue saw improvements in fatigue-related measures, those with pronounced malaise experienced gains in both malaise and cognitive function, and patients with severe brain fog demonstrated measurable improvements in cognitive impairment endpoints. Looking ahead, Do said BioVie expects biomarker data from the study within the next several months. The company hopes those results will provide further insight into the biological mechanisms behind Bezisterim’s effects and help validate the therapeutic approach. Following the biomarker analysis, BioVie plans to request an end-of-Phase 2 meeting with the U.S. Food and Drug Administration to discuss the design of a Phase 3 trial. The company is also pursuing grant funding opportunities to help support the next stage of development for its long COVID program. Beyond long COVID, BioVie continues to advance Bezisterim as a potential treatment for Parkinson’s disease. Do said the company has been working closely with clinical experts to finalize the design of a registrational Phase 3 study and believes it has identified the appropriate endpoints, study size and duration needed to demonstrate the drug’s potential to address both motor and non-motor symptoms of Parkinson’s. He added that Bezisterim could potentially become the first therapy capable of not only improving symptoms but also modifying disease progression. BioVie expects to receive formal FDA feedback on its Phase 3 Parkinson’s trial design before the end of the year. proactiveinvestors #biovieince #nasdaq #bivi #Bezisterim #LongCOVID #Healthcare #Biotech #ClinicalTrials #BrainFog #Fatigue #MedicalResearch #ParkinsonsDisease #DrugDevelopment #FDA #Biotechnology #LifeSciences #HealthcareInnovation
Dow slides as oil nears $100, US-Canada trade tensions escalate
An escalating US-Canada trade dispute added to inflation concerns at the start of the holiday-shortened week
BioVie advances Parkinson’s Phase 3 development program with FDA engagement
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson’s disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson’s disease...
BioVie Announces Update to Parkinson’s Phase 3 Development Program
Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson’s DiseaseCARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of engagement with the Food and Drug Administration (FDA) to advance the Company’s Phase 3 de
BioVie Announces Bezisterim Has Potential To Treat Parkinson's Disease; To Hold Talks With FDA Over Phase 3 Trial Design
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-28 | Palumbo Joseph M | +4,843 | $2.16 | $10,461 |
| 2026-08-28 | Chappell Amy Suzon | +727 | $2.16 | $1,570 |
| 2026-08-28 | KIM JOANNE WENDY | +2,500 | $2.18 | $5,450 |
| 2026-08-27 | DO CUONG V | +15,210 | $2.08 | $31,637 |
| 2026-01-05 | Palumbo Joseph M | +132,000 | - | - |
| 2026-01-05 | KIM JOANNE WENDY | +110,100 | - | - |
| 2026-01-05 | Sherman Michael Edward | +341,100 | - | - |
| 2026-01-05 | Sherman Michael Edward | +80,000 | - | - |
| 2026-01-05 | Farag Kameel D. | +57,500 | - | - |
| 2026-01-05 | Chappell Amy Suzon | +57,500 | - | - |
| 2026-01-05 | Lang James Paul | +330,500 | - | - |
| 2026-01-05 | Lang James Paul | +90,000 | - | - |
| 2026-01-05 | DO CUONG V | +665,300 | - | - |
| 2026-01-05 | ROGICH SIGMUND | +141,100 | - | - |
| 2026-01-05 | ROGICH SIGMUND | +70,000 | - | - |